专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

US20110112023A1 VON WILLEBRAND FACTOR OR FACTOR VIII AND VON WILLEBRAND FACTOR FOR THE TREATMENT OF COAGULOPATHY INDUCED BY INHIBITORS OF THROMBOCYTES 有权
标题翻译： VON WILLEBRAND因子或因子VIII和VON WILLEBRAND因子治疗凝血酶抑制剂诱导的凝血酶
公开(公告)号：US20110112023A1
公开(公告)日：2011-05-12
申请号：US13003139
申请日：2009-07-10
申请人： Gerhard Dickneite , Ingo Pragst , Henrique Lessa , Thorsten Haas , Stefan Zeitler
发明人： Gerhard Dickneite , Ingo Pragst , Henrique Lessa , Thorsten Haas , Stefan Zeitler
IPC分类号： A61K38/37 , A61K38/36 , A61P7/00 , A61P7/04
CPC分类号： A61K38/36 , A61K35/13 , A61K38/37 , A61K2300/00
摘要： The present invention relates to a von Willebrand Factor for use in the treatment and/or prevention of a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes. Furthermore, the present invention relates to a method of treating and/or preventing a disorder related to a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes comprising administering a pharmaceutically effective amount of a von-Willebrand-Factor (vWF) to a patient in need thereof. The present invention also relates to a composition comprising vWF and a composition comprising FVIII for simultaneous, separate or sequential use for use in the treatment and/or prevention of a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes.
摘要翻译：本发明涉及一种用于治疗和/或预防与抑制凝血细胞的物质诱导的血栓形成相关的出血事件的血管性血友病因子。此外，本发明涉及治疗和/或预防与由抑制凝血细胞的物质引起的血栓形成相关的出血事件相关疾病的方法，其包括向患者施用药学有效量的血管性血友病因子（vWF）需要它。本发明还涉及包含vWF的组合物和包含用于同时，分开或顺序使用的FVIII的组合物，其用于治疗和/或预防与抑制凝血细胞的物质诱导的血栓形成相关的出血事件。

12. 发明授权

US5006515A Pharmaceuticals, phosphorus-containing 2-isoxazolines and isoxazoles contained therein 失效
标题翻译：药物，其中含有含磷的2-异恶唑啉和异恶唑
公开(公告)号：US5006515A
公开(公告)日：1991-04-09
申请号：US262635
申请日：1988-10-26
申请人： Wilfried Schwab , Robert R. Bartlett , Ulrich Gebert , Hans U. Schorlemmer , Gerhard Dickneite , Hans H. Sedlacek
发明人： Wilfried Schwab , Robert R. Bartlett , Ulrich Gebert , Hans U. Schorlemmer , Gerhard Dickneite , Hans H. Sedlacek
IPC分类号： A61K31/675 , A61K39/39 , A61P35/00 , A61P37/00 , C07F9/40 , C07F9/653 , C07F9/6574
CPC分类号： C07F9/653 , A61K31/675
摘要： Pharmaceuticals containing or composed of at least one compound of the formula I and/or one of its physiologically tolerated salts where appropriate, where the compounds of the formula I can, where appropriate, be in the form of pure stereoisomers or mixtures thereof; formula I is: ##STR1## in which R.sup.1 =organic radical or halogen,A=C,C single or C,C double bond,n=0, 1 or 2, and ##STR2## R.sup.2 and R.sup.3 =H or optionally substituted aliphatic radical. The pharmaceuticals are suitable for the prophylaxis and/or treatment of diseases of the immune system, especially of tumors, infections and/or autoimmune diseases of the human or animal body and for use as adjuvants for vaccines.Some of the compounds of the formula I are new; the compounds can be prepared by special processes.
摘要翻译：含有或由至少一种式I化合物和/或其适当的生理学耐受盐组成的药物，其中式I化合物在适当时可以是纯立体异构体或其混合物的形式; 式I是：其中R 1 =有机基团或卤素，A = C，C单或C，C双键，n = 0,1或2，X和Y =烷基或= OR 2 或具有R2和R3 = H的NR2R3或任选取代的脂族基团。该药物适用于预防和/或治疗免疫系统疾病，特别是人或动物体的肿瘤，感染和/或自身免疫性疾病的疾病，并且可用作疫苗佐剂。一些式I的化合物是新的; 该化合物可以通过特殊方法制备。

13. 发明授权

US09352016B2 Factor XII inhibitors for the administration with medical procedures comprising contact with artificial surfaces 有权
标题翻译：用于用医学程序给药的因子XII抑制剂，包括与人造表面接触
公开(公告)号：US09352016B2
公开(公告)日：2016-05-31
申请号：US14004066
申请日：2012-03-09
申请人： Stefan Zeitler , Marc Nolte , Stefan Schulte , Gerhard Dickneite , Ingo Pragst
发明人： Stefan Zeitler , Marc Nolte , Stefan Schulte , Gerhard Dickneite , Ingo Pragst
IPC分类号： A61K9/00 , A61K36/00 , A61K38/16 , A61K38/55 , A61K38/57 , C07K16/36 , C07K16/40 , A61K31/727 , A61K38/17 , A61K47/48
CPC分类号： A61K38/1767 , A61K31/727 , A61K38/16 , A61K38/556 , A61K38/57 , A61K38/58 , A61K39/3955 , A61K47/643 , A61K47/65 , A61L33/0041 , A61L33/0082 , A61L33/128 , A61L2300/252 , A61L2300/256 , A61L2300/42 , A61L2420/00 , C07K16/36 , C07K16/40 , C07K2317/76
摘要： An inhibitor of FXII/FXIIa for the prevention of the formation and/or stabilization of thrombi during and/or after a medical procedure performed on a human or animal subject comprising contacting blood of said human or animal subject with artificial surfaces, wherein said inhibitor of FXII/FXIIa is administered before and/or during and/or after said medical procedure.
摘要翻译： FXII / FXIIa的抑制剂，用于在对人或动物受试者进行的医疗过程期间和/或之后防止血栓的形成和/或稳定化，包括使人或动物受试者的血液与人造表面接触，其中所述抑制剂 FXII / FXIIa在所述医疗程序之前和/或期间和/或之后施用。

14. 发明申请

US20100093607A1 SYNERGISTIC THERAPEUTIC USE OF PROTHROMBIN COMPLEX CONCENTRATES WITH FVIII CONCENTRATES 有权
标题翻译：丙泊酚复合浓度与FVIII浓度的协同治疗
公开(公告)号：US20100093607A1
公开(公告)日：2010-04-15
申请号：US12520773
申请日：2007-12-18
申请人： Gerhard Dickneite
发明人： Gerhard Dickneite
IPC分类号： A61K38/36 , A61K38/37
CPC分类号： A61K38/37 , A61K38/36 , A61K38/4846
摘要： The field of the invention is the treatment of acquired bleeding, a clinical condition associated with severe traumatic, perk or post-operative bleeding. A novel treatment is proposed in which synergistic procoagulatory properties of Prothrombin Complex Concentrates (PCC) together with medicaments comprising FVIII and/or vWF are exploited.
摘要翻译：本发明的领域是获得性出血的治疗，与严重创伤性，外伤或术后出血相关的临床病症。提出了一种新的治疗方法，其中利用了凝血酶原复合物浓缩物（PCC）与包含FVIII和/或vWF的药物的协同促进特性。

15. 发明授权

US5274098A Amidinophenylalanine derivatives, process for their preparation, their use and compositions containing them 失效
标题翻译：脒基苯丙氨酸衍生物，其制备方法，其用途和含有它们的组合物
公开(公告)号：US5274098A
公开(公告)日：1993-12-28
申请号：US864547
申请日：1992-04-07
申请人： StuWerner , Gerhard Dickneite
发明人： StuWerner , Gerhard Dickneite
IPC分类号： A61K31/18 , A61K31/555 , A61K38/00 , A61K38/05 , A61P7/02 , C07C303/40 , C07C311/49 , C07D223/16 , C07D295/10 , C07K5/06 , C07D211/06 , C07D405/10
CPC分类号： C07K5/06026 , C07C45/62 , C07C45/68 , C07D223/16 , A61K38/00
摘要： Amidinophenylalanine derivatives, a process for their preparation, their use and pharmaceutical compositions which contain these compounds are described.
摘要翻译：描述了脒基苯丙氨酸衍生物，其制备方法及其用途和含有这些化合物的药物组合物。

16. 发明授权

US09624307B2 Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs 有权
公开(公告)号：US09624307B2
公开(公告)日：2017-04-18
申请号：US14003963
申请日：2012-03-09
申请人： Matthias Nahrendorf , Ralph Weissleder , Gerhard Dickneite , Guido Stoll , Marc Nolte
发明人： Matthias Nahrendorf , Ralph Weissleder , Gerhard Dickneite , Guido Stoll , Marc Nolte
IPC分类号： A61K38/48 , C07K14/81 , C07K16/40 , A61K38/55 , A61K38/57 , A61K49/00 , A61K49/14 , G01N33/50 , A61K39/395 , C07K16/36
CPC分类号： C07K16/40 , A61K38/4846 , A61K38/556 , A61K38/57 , A61K39/3955 , A61K49/0004 , A61K49/0008 , A61K49/14 , C07K14/811 , C07K14/8114 , C07K16/36 , G01N33/5088 , G01N2500/10
摘要： Silent brain ischemia (SBI) or ischemia of other organs can result from an embolism that is introduced into the arterial system during a medical procedure. The application provides a method of administering a FXII inhibitor in a patient receiving a medical procedure and animal models useful for studying ischemia including SBI and ischemia in other organs, and for evaluating candidate therapeutics.

17. 发明授权

US08603979B2 von Willebrand factor or factor VIII and von Willebrand factor for the treatment of coagulopathy induced by inhibitors of thrombocytes 有权
公开(公告)号：US08603979B2
公开(公告)日：2013-12-10
申请号：US13003139
申请日：2009-07-10
申请人： Gerhard Dickneite , Ingo Pragst , Henrique Lessa , Thorsten Haas , Stefan Zeitler
发明人： Gerhard Dickneite , Ingo Pragst , Henrique Lessa , Thorsten Haas , Stefan Zeitler
IPC分类号： A61K38/57 , A61K38/36 , C07K14/745 , A61P7/02
CPC分类号： A61K38/36 , A61K35/13 , A61K38/37 , A61K2300/00
摘要： The present invention relates to a von Willebrand Factor for use in the treatment and/or prevention of a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes. Furthermore, the present invention relates to a method of treating and/or preventing a disorder related to a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes comprising administering a pharmaceutically effective amount of a von-Willebrand-Factor (vWF) to a patient in need thereof. The present invention also relates to a composition comprising vWF and a composition comprising FVIII for simultaneous, separate or sequential use for use in the treatment and/or prevention of a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes.

18. 发明申请

US20120258072A1 Interleukin-11 Fusion Proteins 审中-公开
标题翻译：白细胞介素-11融合蛋白
公开(公告)号：US20120258072A1
公开(公告)日：2012-10-11
申请号：US13278757
申请日：2011-10-21
申请人： Monika Kröz , Gerhard Dickneite , Hans-Peter Hauser , Thomas Weimer , Darrell Sleep
发明人： Monika Kröz , Gerhard Dickneite , Hans-Peter Hauser , Thomas Weimer , Darrell Sleep
IPC分类号： C07K19/00 , A61P7/02 , A61P1/00 , C12N5/10 , C12P21/02 , C12N15/63 , C12N1/19 , A61K38/20 , C12N15/62
CPC分类号： A61K38/38 , A61K38/2073 , C07K14/5431 , C07K14/76 , C07K14/765 , C07K2319/31 , Y02A50/473
摘要： The invention relates to proteins comprising Interleukin 11 (IL-11) (including, but not limited to, fragments and variants thereof), which exhibit thrombopoietic or anti-inflammatory properties, fused to albumin (including, but not limited to, fragments or variants of albumin). These fusion proteins are herein collectively referred to as “albumin fusion proteins of the invention”. These fusion proteins exhibit extended shelf-life and/or pharmacokinetic properties and/or extended or therapeutic activity. The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits. The invention also encompasses nucleic acid molecules encoding the albumin fusion proteins of the invention, as well as vectors containing these nucleic acids, host cells transformed with these nucleic acids and vectors, and methods of making the albumin fusion proteins of invention using these nucleic acids, vectors, and/or host cells. The invention also relates to compositions and methods for treatment or prophylaxis of thrombocytopenia or inflammatory diseases.
摘要翻译：本发明涉及包含白细胞介素11（IL-11）（包括但不限于其片段和变体）的蛋白质，其表现出与白蛋白融合的血小板生成或抗炎特性（包括但不限于片段或变体的白蛋白）。这些融合蛋白在本文中统称为白蛋白融合蛋白。这些融合蛋白具有延长的保质期和/或药代动力学性质和/或延长或治疗活性。本发明包括治疗性白蛋白融合蛋白，组合物，药物组合物，制剂和试剂盒。本发明还包括编码本发明的白蛋白融合蛋白的核酸分子，以及含有这些核酸的载体，用这些核酸和载体转化的宿主细胞，以及使用这些核酸制备本发明的白蛋白融合蛋白的方法，载体和/或宿主细胞。本发明还涉及用于治疗或预防血小板减少症或炎性疾病的组合物和方法。

19. 发明申请

US20080292581A1 Interleukin-11 Fusion Proteins 审中-公开
标题翻译：白细胞介素-11融合蛋白
公开(公告)号：US20080292581A1
公开(公告)日：2008-11-27
申请号：US10584438
申请日：2004-12-03
申请人： Monika Kroz , Gerhard Dickneite , Hans-Peter Hauser , Thomas Weimer , Darrell Sleep
发明人： Monika Kroz , Gerhard Dickneite , Hans-Peter Hauser , Thomas Weimer , Darrell Sleep
IPC分类号： C07K14/54 , C12N15/24 , C12N15/81 , C12N15/85 , C12P21/02 , C12N5/10 , C12N1/19 , A61P1/00 , A61P3/00 , A61K38/20
CPC分类号： A61K38/38 , A61K38/2073 , C07K14/5431 , C07K14/76 , C07K14/765 , C07K2319/31 , Y02A50/473
摘要： The invention relates to proteins comprising Interleukin 11 (IL-11) (including, but not limited to, fragments and variants thereof), which exhibit thrombopoietic or antiinflammatory properties, fused to albumin (including, but not limited to fragments or variants of albumin). These fusion proteins are herein collectively referred to as “albumin fusion proteins of the invention”. These fusion proteins exhibit extended shelf-life and/or pharmacokinetic properties and/or extended or therapeutic activity. The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits. The invention also encompasses nucleic acid molecules encoding the albumin fusion proteins of the invention, as well as vectors containing these nucleic acids, host cells transformed with these nucleic acids and vectors, and methods of making the albumin fusion proteins of the invention using these nucleic acids, vectors, and/or host cells. The invention also relates to compositions and methods for treatment or prophylaxis of thrombocytopenia or inflammatory diseases.
摘要翻译：本发明涉及与白蛋白（包括但不限于白蛋白的片段或变体）融合的表现出血小板生成或抗炎特性的白介素11（IL-11）（包括但不限于其片段和变体）的蛋白质，。这些融合蛋白在本文中统称为“本发明的白蛋白融合蛋白”。这些融合蛋白具有延长的保质期和/或药代动力学性质和/或延长或治疗活性。本发明包括治疗性白蛋白融合蛋白，组合物，药物组合物，制剂和试剂盒。本发明还包括编码本发明的白蛋白融合蛋白的核酸分子以及含有这些核酸的载体，用这些核酸和载体转化的宿主细胞，以及使用这些核酸制备本发明的白蛋白融合蛋白的方法，载体和/或宿主细胞。本发明还涉及用于治疗或预防血小板减少症或炎性疾病的组合物和方法。

20. 发明授权

US5627283A Amidinophenylalanine derivatives, a process for the preparation thereof, use thereof and agents containing these as anticoagulants 失效
标题翻译：脒基苯丙氨酸衍生物，其制备方法，其用途和含有它们的试剂作为抗凝剂
公开(公告)号：US5627283A
公开(公告)日：1997-05-06
申请号：US475691
申请日：1995-06-07
申请人： Werner St uber , Gerhard Dickneite , Rainer Koschinsky , Cenek Kolar
发明人： Werner St uber , Gerhard Dickneite , Rainer Koschinsky , Cenek Kolar
IPC分类号： A61K38/00 , A61K38/05 , A61P7/02 , C07K1/06 , C07K1/113 , C07K5/02 , C07K5/06 , C07K5/065 , C07K5/072 , C07K9/00 , G01N33/53 , C07D211/06 , C07H21/04
CPC分类号： C07K5/06104 , C07K5/0215 , C07K9/001 , A61K38/00
摘要： Amidinophenylalanine derivatives of the formula I ##STR1## the synthesis of these compounds, the use thereof and pharmaceutical agents which contain these compounds are described.
摘要翻译：描述了式I的脒基苯丙氨酸衍生物（I）这些化合物的合成，其用途和含有这些化合物的药剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式